Scholars Central

Research articlePublished 2020

The Effect of Folic Acid as Anti Fibrosis in Peritoneum of Rat

Authors: Wachid Putranto, Bambang Purwanto, Ambar Mudigdo, Brian Washita, Ari Natali Probandari

Systematic Reviews in Pharmacy

Volume 11 · Issue 11 · Pages 1378–1383

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: One limitations of Peritoneal Dialysis (PD)’s is peritoneal fibrosis, which is a functional and structural change in the peritoneal membrane induced by peritoneal dialysate fluid containing high sugar levels. This may cause ultrafiltration (UF) failure leading to progressive loss of dialysis efficacy. Expression of vascular endothelial growth factor (VEGF) increases angiogenesis and vascular permeability, followed by increased macromolecular leakage and ultimately contributes to UF failure. Expression of Transforming Growth Factor-β (TGF-β) induces mesothelial thickening and peritoneal fibrosis. Folic acid inhibits progressivity of Chronic Kidney Disease (CKD) by 21% and improve Glomerular Filtration Rate (GFR) by 10% in hypertensive patients. Folic acid can reduce inflammation as cause of endothelial dysfunction that impact to progressive atherosclerosis. The aim of this study was to evaluate the effect folic acid to reduce the expression of TGF-β, VEGF and peritoneal fibrosis in a male rat treated with PD. Methods: This was an experimental study, with post-test only control group design. Twenty-four Sprague dawley rats are divided into four groups: CKD rat group (Group 1), PD liquid 4,25% (Group 2), CKD PD and folic acid 120 µg/day oral (Group 3), and CKD PD & lisinopril 1,5 mg/day oral (Group 4). After 4 weeks, rat sacrificed expression of TGF-β, VEGF and peritoneal fibrosis are conducted by histopathology with masson’s trichrome and immunology with anti-human-TGF-β and anti VEGF. Statistical analys is using Kruskal Willis test. p-value <0.05 was considered statistically significant. Results: Compared with CKD PD group, folic acid group shown decrease of TGF-β expression (p = 0.002), VEGF expression (p = 0.01), and peritoneal fibrosis (p = 0.001). Lisinopril group also showed decrease of TGF-β expression (p = 0.06), VEGF expression (p = 0.09), but not for peritoneal fibrosis. Folic acid decreased TGF-β expression more than lisinopril. The decrease in VEGF expression in the lisinopril group was greater than folic acid group. Conclusion: Folic acid shown lower of TGF-β and VEGF expression and reduced and peritoneum fibrosis better than control or lisinopril and statistically significant. Folic acid is potential as therapy agent to reduce peritoneal fibrosis in PD’s patient

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Systematic Reviews in Pharmacy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalSystematic Reviews in Pharmacy
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Wachid Putranto”
  • BylineArticles whose byline prints “Bambang Purwanto”
  • BylineArticles whose byline prints “Ambar Mudigdo”
  • BylineArticles whose byline prints “Brian Washita”
  • BylineArticles whose byline prints “Ari Natali Probandari”